A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma

Lung squamous cell carcinoma (LUSC) comprises 20–30% of all lung cancers. Immunotherapy has significantly improved the prognosis of LUSC patients; however, only a small subset of patients responds to the treatment. Therefore, we aimed to develop a novel multi-gene signature associated with the immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qin, Gong, Han, Liu, Jing, Ye, Mao, Zou, Wen, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372044/
https://www.ncbi.nlm.nih.gov/pubmed/35953696
http://dx.doi.org/10.1038/s41598-022-17735-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372044/
https://www.ncbi.nlm.nih.gov/pubmed/35953696
http://dx.doi.org/10.1038/s41598-022-17735-6

Ejemplares similares